Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed the day trading at $29.84 down -2.64% from the previous closing price of $30.65. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 985270 shares were traded.
Ratios:
For a better understanding of HRMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.73. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.38.
On September 25, 2023, Goldman Downgraded its rating to Sell which previously was Neutral and also lowered its target price recommendation from $40 to $31.
On September 07, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $59.Berenberg initiated its Buy rating on September 07, 2023, with a $59 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Dierks Jeffrey sold 11,979 shares for $32.00 per share. The transaction valued at 383,328 led to the insider holds 0 shares of the business.
Dierks Jeffrey sold 194 shares of HRMY for $6,208 on Mar 08 ’24. The CHIEF COMMERCIAL OFFICER now owns 0 shares after completing the transaction at $32.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRMY now has a Market Capitalization of 1.69B and an Enterprise Value of 1.53B. As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.99, and their Forward P/E ratio for the next fiscal year is 7.43. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.91 while its Price-to-Book (P/B) ratio in mrq is 3.63. Its current Enterprise Value per Revenue stands at 2.64 whereas that against EBITDA is 6.93.
Stock Price History:
Over the past 52 weeks, HRMY has reached a high of $39.26, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is 32.15, while the 200-Day Moving Average is calculated to be 31.71.
Shares Statistics:
Over the past 3-months, HRMY traded about 346.15K shares per day on average, while over the past 10 days, HRMY traded about 358.68k shares per day. A total of 56.77M shares are outstanding, with a floating share count of 30.75M. Insiders hold about 45.84% of the company’s shares, while institutions hold 62.60% stake in the company. Shares short for HRMY as of Mar 15, 2024 were 6.09M with a Short Ratio of 17.58, compared to 6.41M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.72% and a Short% of Float of 32.16%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of $0.62 for the current quarter, with a high estimate of $0.72 and a low estimate of $0.49, while EPS last year was $0.48. The consensus estimate for the next quarter is $0.76, with high estimates of $0.87 and low estimates of $0.62.
Analysts are recommending an EPS of between $3.45 and $2.45 for the fiscal current year, implying an average EPS of $2.91. EPS for the following year is $4.02, with 7 analysts recommending between $4.92 and $3.35.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $719.2M, while the lowest revenue estimate was $700.38M, resulting in an average revenue estimate of $711.79M. In the same quarter a year ago, actual revenue was $582.02M, up 22.30% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $840.62M in the next fiscal year. The high estimate is $889.8M and the low estimate is $788.75M. The average revenue growth estimate for next year is up 18.10% from the average revenue estimate for this year.
